Table 1 Baseline patient characteristics
Parameters | Value |
|---|---|
Median age, y (range) | 62 (19–84) |
Men/women | 27/22 |
Chronic phase/accelerated phase | 45/4 |
Median duration of CML, months (range) | 46.0 (3.6-208.2) |
Median duration of imatinib therapy, months (range) | 43.4 (3.1-101.9) |
Imatinib-resistant/-intolerant | 33/16 |
Prior TKI therapy | Â |
Imatinib/dasatinib/bosutinib | 49/4/2 |
Other prior therapy | Â |
Interferon/hydroxyurea/AraC/BU | 9/8/1/1 |
Cytogenetic response at baseline, Ph +% |  |
>95/>65-95/>35-65/>0-36/0 | 14/6/4/2/23 |
BCR-ABL1 level at baseline, IS% | Â |
>10/>1-10/>0.1-1/≤ 0.1 | 18/7/10/14 |
Additional chromosomal abnormality, n (%) | 5 (15.2) |
BCR-ABL1 mutations, n (%) | 6 (12.2) |